Real-World Evidence Research
Specialist end-to-end consultation to strengthen evidence strategies and improve research outcomes.
Regulatory-grade data for more impactful research
TriNetX data is research-grade and research-ready. No matter the analyses you conduct with our data, our experts are on hand to guide you from concept to publication.
From exploratory research to regulatory and safety studies, we help you turn our data into impactful evidence, tailored to your specific needs.
How can we support your research?
Identify unmet needs, assess disease burden and progression, and make smarter internal decisions with robust R&D studies informed by real-world data.
Demonstrate intervention value, healthcare utilization, and patient journeys through rigorous, data-driven HEOR studies.
Ensure compliance and support regulatory requirements with validated real-world evidence.
Our RWE research services
Explore how we help you design and deliver quality data-driven research.
Develop fit-for-purpose study designs and strategies that produce robust, actionable outcomes.
Create detailed study protocols and statistical analysis plans (SAPs) that align with community standards to ensure quality, integrity, and acceptance.
Deliver rigorous, process-driven studies, including expertly developed reports, manuscripts, and abstracts to share findings with targeted audiences.
Collaborate with our industry and academic experts to drive innovation and address unique scientific questions.
Want to learn more?
Explore our related insights
The era of the blockbuster drug and one-size-fits-all medicine is ending. What’s replacing it demands a fundamentally different approach to finding the right patients before a trial begins.
In this session, TriNetX and Parexel share a modern feasibility workflow designed for clinical operations teams, including non-medical users empowered through natural language and AI translation.
IBD involves a chronically inflamed gastrointestinal (GI) tract, and the GI side effect profile of GLP-1 receptor agonists raised legitimate questions about tolerability and disease exacerbation in these patients.
Even when the data foundation is right, even when the AI is producing high-quality insights, why are so many clinical operations teams not seeing the productivity gains the technology promised?
Contact TriNetX
Need to reach out? We’re here to help.
"*" indicates required fields
